Ippei Chikazawa

Kahoku, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC.

The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC.

Journal: The Prostate

Published: April 22, 2026

Quality-of-Life in CRPC Patients Treated With Enzalutamide Versus Abiraterone: Impact of Standard and Modified Dosing.

Quality-of-Life in CRPC Patients Treated With Enzalutamide Versus Abiraterone: Impact of Standard and Modified Dosing.

Journal: Clinical genitourinary cancer

Published: March 27, 2026

Quantitative analysis of dynamic-contrast MRI for the assessment of prostate cancer in the transition zone.

Quantitative analysis of dynamic-contrast MRI for the assessment of prostate cancer in the transition zone.

Journal: Urologia

Published: January 26, 2026

Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa.

Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: January 15, 2026

Sequential Enzalutamide-Docetaxel Versus Abiraterone-Docetaxel Therapy in Castration-Resistant Prostate Cancer: A Subanalysis of the ENABLE Study.

Sequential Enzalutamide-Docetaxel Versus Abiraterone-Docetaxel Therapy in Castration-Resistant Prostate Cancer: A Subanalysis of the ENABLE Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: December 22, 2025

Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder Castration-Resistant Prostate Cancer Patients: A Sub-Analysis From the ENABLE Study.

Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder Castration-Resistant Prostate Cancer Patients: A Sub-Analysis From the ENABLE Study.

Journal: The Prostate

Published: January 21, 2025

Summary of the clinical practice guideline for the management of urinary stones, third edition.

Summary of the clinical practice guideline for the management of urinary stones, third edition.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: November 04, 2024

Integrated Bioinformatic Analyses Reveal Thioredoxin as a Putative Marker of Cancer Stem Cells and Prognosis in Prostate Cancer.

Integrated Bioinformatic Analyses Reveal Thioredoxin as a Putative Marker of Cancer Stem Cells and Prognosis in Prostate Cancer.

Journal: Cancer informatics

Published: August 20, 2024

Anatomical approach in magnetic resonance imaging and ultrasonography fusion biopsy for prostate cancer detection: a cross-sectional study.

Anatomical approach in magnetic resonance imaging and ultrasonography fusion biopsy for prostate cancer detection: a cross-sectional study.

Journal: BMC urology

Published: August 14, 2024

Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: A subanalysis from the ENABLE study for PCa.

Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: A subanalysis from the ENABLE study for PCa.

Journal: The Prostate

Published: June 12, 2024

Pharmacotherapy for patients with calcium oxalate stones and abnormal urine chemistry: A systematic review and meta-analysis for the Japanese Clinical Practice Guidelines for the Management of Urinary Stones, Third Edition.

Pharmacotherapy for patients with calcium oxalate stones and abnormal urine chemistry: A systematic review and meta-analysis for the Japanese Clinical Practice Guidelines for the Management of Urinary Stones, Third Edition.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: February 12, 2024

Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa.

Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa.

Journal: Cancers

Published: December 05, 2023

Showing 1-12 of 20

Last Updated: 09/26/2026